Alembic Pharma Receives 4 Observations From USFDA For Panelav Facility
Alembic Pharmaceuticals on Monday said that US health regulator has conducted an inspection at it Panelav facility in Gujarat and issued Form 483 with four procedural observations."The US Food and Drug Administration (USFDA) has conducted an inspection at Alembic Pharmaceuticals general oral solid formulation facility located at Panelav from 9-13 March, 2020," the drug firm said in a filing to the BSE.This was a scheduled inspection, and at the end of the inspection, the USFDA issued a Form 483 with four procedural observations.None of the observations are related to data integrity or repetitive in nature."The company will provide comprehensive corrective action report to address each observation. The company is committed to maintaining highest quality standards that meet USFDA standards," it said.The US health regulator issues observations by means of a FDA Form 483 notifying the company's management of objectionable conditions at the facility inspected.
Let’s apply Data-Driven Pricing to Your APIs
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions!
Learn More!